Printer Friendly

Sutro Partners with The Leukemia and Lymphoma Society Partner on Lymphoma and Multiple Myeloma Treatment.

M2 PHARMA-August 15, 2018-Sutro Partners with The Leukemia and Lymphoma Society Partner on Lymphoma and Multiple Myeloma Treatment

(C)2018 M2 COMMUNICATIONS

- US-based drugmaker Sutro Biopharma, Inc., and The Leukemia and Lymphoma Society, or LLS, are partnering to develop STRO-001, Sutro's CD74-targeting antibody-drug conjugate, to treat relapsed and/or refractory multiple myeloma and non-Hodgkin's lymphoma, the principals said.

CD74 is a protein highly expressed in B-cell malignancies such as myeloma and lymphoma.

LLS has agreed to contribute clinical development funding for STRO-001, Sutro's first internally-developed product candidate, through its Therapy Acceleration Program, which forges collaborations with biotechnology companies to help bring innovative therapies to patients faster.

Sutro intends to use the funding for a Phase 1 study, initiated in April of this year, to evaluate STRO-001 for treating multiple myeloma, diffuse large B-cell lymphoma, mantle cell lymphoma and indolent lymphomas, such as follicular lymphoma.

The clinical trial is currently open and enrolling patients at city of Hope Comprehensive Cancer Center, Duarte, CA; Medical College of Wisconsin, Milwaukee; Texas Oncology, Austin; Rocky Mountain Cancer Centers, Aurora, CO; and Virginia Cancer Specialists in Fairfax. Sutro plans to add more sites later this year.

The study's primary outcome measures are safety and tolerability of STRO-001 in dose escalation, and preliminary anti-tumor activity in dose expansion. This is the first clinical trial on a product candidate created with cell-free protein synthesis.

Sutro is obligated to make payments to The Leukemia and Lymphoma Society based on pre-specified late-stage clinical development, regulatory and commercialization milestones.

Financial terms of the partnership have not been disclosed.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Aug 15, 2018
Words:269
Previous Article:Tdap Vaccination for Pregnant Women Does Not Increase Risk of Autism, Kaiser Permanente Study Finds.
Next Article:Regeneron Provides Regulatory Update on Eylea Injection sBLA in Wet Age-Related Macular Degeneration.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |